Browse FHOD3

Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Note=Main part of the protein localizes to actin fibers and the remaining part displays filamentous staining. ; SUBCELLULAR LOCATION: Isoform 4: Cytoplasm, myofibril, sarcomere, Z line. Note=Threonine phosphorylation in isoform 4-specific sequence TDTDEEEEVE is required for targeting to myofibrils in cardiomyocytes.
Domain PF02181 Formin Homology 2 Domain
Function

Actin-organizing protein that may cause stress fiber formation together with cell elongation (By similarity). Isoform 4 may play a role in actin filament polymerization in cardiomyocytes.

> Gene Ontology
 
Biological Process GO:0007015 actin filament organization
GO:0007507 heart development
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010639 negative regulation of organelle organization
GO:0010927 cellular component assembly involved in morphogenesis
GO:0014706 striated muscle tissue development
GO:0030041 actin filament polymerization
GO:0030239 myofibril assembly
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030837 negative regulation of actin filament polymerization
GO:0031032 actomyosin structure organization
GO:0031333 negative regulation of protein complex assembly
GO:0032271 regulation of protein polymerization
GO:0032272 negative regulation of protein polymerization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0035051 cardiocyte differentiation
GO:0042692 muscle cell differentiation
GO:0043254 regulation of protein complex assembly
GO:0045214 sarcomere organization
GO:0048738 cardiac muscle tissue development
GO:0051146 striated muscle cell differentiation
GO:0051258 protein polymerization
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051639 actin filament network formation
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0055003 cardiac myofibril assembly
GO:0055006 cardiac cell development
GO:0055007 cardiac muscle cell differentiation
GO:0055013 cardiac muscle cell development
GO:0060537 muscle tissue development
GO:0090066 regulation of anatomical structure size
Molecular Function GO:0003779 actin binding
Cellular Component GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030018 Z disc
GO:0031674 I band
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FHOD3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FHOD3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.39; FDR: 0.03680 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FHOD3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2330.628
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.7990.496
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.970.188
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2050.642
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1420.951
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6470.816
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2730.638
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3110.808
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2860.832
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3710.762
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5240.767
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5370.00771
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FHOD3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.17.71.41
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7100-83.30.286
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FHOD3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FHOD3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FHOD3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FHOD3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FHOD3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FHOD3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFHOD3
Nameformin homology 2 domain containing 3
Aliases FHOS2; KIAA1695; FLJ22297; FLJ22717; Formactin2; formactin-2; formin homolog overexpressed in spleen 2; hFHO ......
Chromosomal Location18q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FHOD3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.